Long response to eribulin in breast cancer: a case report. (August 2015)

• Record Type: Journal Article
• Authors: Borgonovo, Karen; Petrelli, Fausto; Cabiddu, Mary; Ghilardi, Mara; Coinu, Andrea; Seghezzi, Silvia; Barni, Sandro
• Is Part Of: Future oncology. Volume 11(2015)Supplement 15
• Page Start: 3
• Page End: 8
• Publication Date: 2015-08
• Subjects: breast cancer -- chemotherapy -- eribulin; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.146
• Languages: English
• ISSNs: 1479-6694

Abstract

No definitive cure is available for metastatic breast cancer and current therapies mainly focus on symptom control and minimization of adverse events to extend survival and maintain a good quality of life. Current treatment options include hormonal and chemotherapeutic agents which are characterized by different toxicity profiles and are selected based on patients' performance status and prior therapies. Eribulin is a microtubule dynamic inhibitor which acts by sequestering tubulin molecules into aggregates, thus preventing microtubule growth and causing apoptosis. Many studies show that heavily pretreated metastatic breast cancer patients benefit from eribulin treatment both in terms of efficacy and for the favorable toxicity profile. In the Phase III EMBRACE study, eribulin treatment resulted in a significant improvement in overall survival. We report here the case of a patient who experienced a time to progression of several months with eribulin after three lines of chemotherapy and two lines of hormonal therapy.